Marie-Ange M. R.
- Country
- France
- Department
- 03311: Service d' Oncologie Médicale
Research Overview
- Evaluation of Preoperative Durvalumab (MEDI4736) in Patients with Early-Stage Untreated Small Triple Negative Breast Cancer
- ISIdE: Open label, multicentric, single-arm phase IIIB trial to evaluate the safety and efficacy of sacituzumab govitecan in triple negative metastatic breast cancer patients with a biomarker analysis.
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Data & Insights
Has run more than one trial at 491 of 869 partner sites.
Specializations
Triple Negative Breast Cancer
Specializes in innovative therapeutic approaches for triple-negative breast cancer (TNBC), with particular focus on early detection and treatment of relapse. Conducts research in neoadjuvant immunotherapy and surveillance strategies using ctDNA-based monitoring.
- Early-stage TNBC treatment
- Disease surveillance methods
- Immunotherapy combinations
HER2-Positive Breast Cancer
Investigates treatment optimization for HER2-positive breast cancer, including therapeutic de-escalation strategies and novel combination approaches. Focuses on both early-stage and metastatic disease management.
- Anti-HER2 targeted therapies
- Treatment de-escalation
- Brain metastases management
Hormone Receptor-Positive Disease
Leads research in hormone receptor-positive breast cancer, exploring novel therapeutic combinations and treatment strategies for advanced disease. Specializes in managing endocrine resistance and developing new treatment approaches.
- CDK4/6 inhibitor combinations
- Endocrine therapy resistance
- Advanced disease management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.